Considerations for Inotrope and Vasopressor Use in Critically Ill Patients With Pulmonary Arterial Hypertension.
J Cardiovasc Pharmacol
; 79(1): e11-e17, 2022 01 01.
Article
em En
| MEDLINE
| ID: mdl-34654789
ABSTRACT: Pulmonary arterial hypertension (PAH) is a rare and progressive cardiopulmonary disease, characterized by pulmonary vasculopathy. The disease can lead to increase pulmonary arterial pressures and eventual right ventricle failure due to elevated afterload. The prevalence of PAH in patients admitted to the intensive care unit (ICU) is unknown, and pulmonary hypertension (PH) in the ICU is more commonly the result of left heart disease or hypoxic lung injury (PH due to left heart disease and PH due to lung diseases and/or hypoxia, respectively), as opposed to PAH. Management of patients with PAH in the ICU is complex as it requires a careful balance to maintain perfusion while optimizing right-sided heart function. A comprehensive understanding of the underlying physiology and underlying hemodynamics is crucial for the management of this population. In this review, we summarized the evidence for use of vasopressors and inotropes in the management of PH and extrapolated the data to patients with PAH. We strongly believe that the understanding of the hemodynamic consequences of inotropes and vasopressors, especially from data in the PH population, can lead to better management of this complex patient population.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Artéria Pulmonar
/
Vasoconstritores
/
Cardiotônicos
/
Função Ventricular Direita
/
Disfunção Ventricular Direita
/
Pressão Arterial
/
Hipertensão Arterial Pulmonar
/
Insuficiência Cardíaca
Tipo de estudo:
Diagnostic_studies
/
Risk_factors_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
J Cardiovasc Pharmacol
Ano de publicação:
2022
Tipo de documento:
Article